Patents for A61P 35 - Antineoplastic agents (221,099)
04/2011
04/12/2011CA2474875C 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2,-a]pyrimidin-5(1h)-one derivatives
04/12/2011CA2438427C Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
04/12/2011CA2426461C Nitrogen-containing aromatic derivatives
04/12/2011CA2414241C Polymeric micelle compositions
04/12/2011CA2388363C Dna polymerase lambda and uses thereof
04/12/2011CA2354153C Compounds and methods for modulating activation of nf-.kappa.b
04/12/2011CA2311409C Treatment with anti-erbb2 antibodies
04/08/2011CA2786834A1 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
04/07/2011WO2011041729A2 Compounds as lysophosphatidic acid receptor antagonists
04/07/2011WO2011041694A2 Compounds as lysophosphatidic acid receptor antagonists
04/07/2011WO2011041613A2 Combination immunotherapy for the treatment of cancer
04/07/2011WO2011041599A2 6-methylvitamin d3 analogs and their uses
04/07/2011WO2011041596A2 19-nor-vitamin d analogs with 1,2-or 3,2-cyclopentene ring
04/07/2011WO2011041590A2 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
04/07/2011WO2011041579A2 (20S,22E)-2-METHYLENE-19-NOR-22-ENE-1α,25-DIHYDROXYVITAMIN D3 ANALOGS
04/07/2011WO2011041512A2 Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases
04/07/2011WO2011041462A2 Polycyclic compounds as lysophosphatidic acid receptor antagonists
04/07/2011WO2011041461A2 Polycyclic compounds as lysophosphatidic acid receptor antagonists
04/07/2011WO2011041399A2 Pi3k (delta) selective inhibitors
04/07/2011WO2011040973A2 Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
04/07/2011WO2011040954A2 Tp53 gene expression and uses thereof
04/07/2011WO2011040613A1 Therapeutic agent for tumor
04/07/2011WO2011040565A1 Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
04/07/2011WO2011040503A1 Method for recovery of sensitivity to anti-cancer agents in cancer cell that acquires resistance to anti-cancer agents
04/07/2011WO2011040495A1 Heparanase-activity inhibitor, wrinkle ameliorating agent containing same, and pharmaceutical composition
04/07/2011WO2011040428A1 Anti-tumor agent and method for screening for same
04/07/2011WO2011040421A1 Screening method
04/07/2011WO2011040220A1 Composition for treatment of pancreatic cancer
04/07/2011WO2011040212A1 Therapeutic agent for brain tumor
04/07/2011WO2011040133A1 Human serum amyloid-a3 antibody and use thereof
04/07/2011WO2011040071A1 Antioxidant composition
04/07/2011WO2011040070A1 Oral composition for alleviation of ultraviolet radiation-induced damage
04/07/2011WO2011039735A2 Compounds with ddx3 inhibitory activity and uses thereof
04/07/2011WO2011039724A1 Antibodies that specifically bind to the epha2 receptor
04/07/2011WO2011039721A1 New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
04/07/2011WO2011039381A1 Antioxidants for use in therapy
04/07/2011WO2011039370A1 Bispecific binding molecules for anti-angiogenesis therapy
04/07/2011WO2011039344A1 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
04/07/2011WO2011039175A1 Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus
04/07/2011WO2011038467A1 Method of treatment of philadelphia chromosome positive leukaemia
04/07/2011WO2011002077A8 TNF-α GENE THERAPY AGENT CONTAINED IN POLYMERIC MICELLE
04/07/2011WO2010138588A3 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
04/07/2011WO2010132440A3 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
04/07/2011WO2010130900A3 Triaminopyrimidine derivatives as cdc25 phosphatase inhibitors
04/07/2011WO2010129340A3 Novel photosensitizer formulations for oral administration
04/07/2011WO2010111713A3 N-linked glycan biosynthesis modulators
04/07/2011WO2010093655A3 Enhanced method for producing stem-like cells from somatic cells
04/07/2011WO2010091104A8 Glucosylceramide synthase inhibitors
04/07/2011WO2010088527A3 Peptides and nanoparticles for therapeutic and diagnostic applications
04/07/2011WO2009146910A8 4, 6-diphenylpyrid-2-0nes against cancer
04/07/2011US20110082427 Bioresorbable embolization microspheres
04/07/2011US20110082407 Combination Therapies for the Treatment of Obesity
04/07/2011US20110082280 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules
04/07/2011US20110082212 Multi-substituted selective androgen receptor modulators and methods of use thereof
04/07/2011US20110082209 Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid
04/07/2011US20110082208 Therapies for cancer using isotopically substituted lysine
04/07/2011US20110082206 Heteroatom containing substituted fatty acids
04/07/2011US20110082200 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
04/07/2011US20110082193 Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
04/07/2011US20110082190 Nucleic Acids Encoding Anti-IL-12 Antibody
04/07/2011US20110082186 Compositions for inhibiting gene expression and uses thereof
04/07/2011US20110082185 Cancer-testis gene silencing agents and uses thereof
04/07/2011US20110082181 Compounds as Lysophosphatidic Acid Receptor Antagonists
04/07/2011US20110082169 Stable SNS-595 Compositions and Methods of Preparation
04/07/2011US20110082168 Compositions for delivering highly water soluble drugs
04/07/2011US20110082164 Polycyclic compounds as lysophosphatidic acid receptor antagonists
04/07/2011US20110082163 Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
04/07/2011US20110082159 METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
04/07/2011US20110082158 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
04/07/2011US20110082151 Sulfonylurea modulators of endothelin receptor
04/07/2011US20110082149 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
04/07/2011US20110082148 Treating, preventing or ameliorating a hyperproliferative disease/disorder
04/07/2011US20110082143 Bicyclic Heteroaryl Compounds
04/07/2011US20110082141 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
04/07/2011US20110082140 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids.
04/07/2011US20110082139 Substituted 8-[6-amino-3-pyridyl]xanthines
04/07/2011US20110082138 Imidazopyridin-2-one derivatives
04/07/2011US20110082135 Inhibitors of akt activity
04/07/2011US20110082131 Triazole derivatives useful as axl inhibitors
04/07/2011US20110082124 Detergent compositions for treatment of lipomas and other conditions
04/07/2011US20110082123 6-Methylvitamin D3 Analogs and Their Uses
04/07/2011US20110082122 19-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring
04/07/2011US20110082121 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses
04/07/2011US20110082116 Novel compounds as cannabinoid receptor ligands
04/07/2011US20110082113 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
04/07/2011US20110082111 Polo-like kinase inhibitors
04/07/2011US20110082107 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
04/07/2011US20110082106 Methods of activating nkt cells
04/07/2011US20110082103 Anoectochilus SPP. polysaccharide extracts for stimulating growth of advantageous bacteria, stimuating release of granulocyte colony-Stimulating factor, modulating T helper cell type I, and/or modulating T helper cell type II and uses of the same
04/07/2011US20110082101 Combinations comprising epothilones and anti-metabolites
04/07/2011US20110082095 Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
04/07/2011US20110082090 Compounds suited as nanocarriers for active agents and their use
04/07/2011US20110082089 Biomarkers for monitoring or predicting the treatment of cancer
04/07/2011US20110082088 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
04/07/2011US20110082073 Modified Cpn10 and PRR signalling
04/07/2011US20110081408 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
04/07/2011US20110081407 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
04/07/2011US20110081406 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
04/07/2011US20110081404 Novel liposome compositions
04/07/2011US20110081403 Histone octamers for increased nucleic acid transfer